TAS::75 0849::TAS

塔斯马尼亚州::75 0849::塔斯马尼亚州

• 批准号: 8164216
• 负责人: EREZ NEVO
• 金额: $ 25万
• 依托单位: ROBIN MEDICAL, INC.
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-30 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8164216
• 关键词: Advanced Malignant Neoplasm; Animal Model; Biological Markers; Biopsy; Cells; Characteristics; Clinical; Devices; Marketing; Molecular Medicine; Molecular Profiling; Morphology; Organ; Patients; Performance; Phase; Procedures; Research; Sampling; System; Testing; Tissue Harvesting; Tissues; cancer diagnosis; improved; prevent; prototype; tumor

Molecular medicine holds promise for advancing cancer diagnosis and treatment if biomarkers can be accurately assessed in tumors. The objective of the project is to develop and test a new biopsy system that stabilizes the target tissue and prevent changes in biomarker levels. The specific objectives of the Phase I project are: 1. to develop tissue harvesting mechanism for the new biopsy device 2. test the cutting performance of the mechanism 3. test tissue harvesting performance of the device in an animal model 4. compare molecular profile of samples obtained with the new device with samples obtained with standard devices. The expected product at the end of the Phase I project is a prototype device that enables tissue harvesting during a biopsy procedure with minimal effect on the biomolecular profile of the cells. A biopsy device that preserves the tissue morphology and stabilizes the biomolecular profile of the cells in the sample is expected to find a wide market and used in many organs. Such a device can facilitate the clinical use of many biomolecular markers that are currently limited to research, to improve the management of patients by the use of individualized therapy that targets the specific characteristics of the tumor in each patient.

如果能够准确评估肿瘤中的生物标志物，分子医学有望推进癌症诊断和治疗。该项目的目标是开发和测试一种新的活检系统，该系统可稳定靶组织并防止生物标志物水平发生变化。第一阶段项目的具体目标是： 1.为新的活检设备开发组织采集机制 2.测试机构的切削性能 3.在动物模型中测试器械的组织采集性能 4.比较使用新装置获得的样品与使用标准装置获得的样品的分子谱。 第一阶段项目结束时的预期产品是一种原型设备，该设备能够在活检过程中进行组织采集，对细胞的生物分子谱的影响最小。保存组织形态并稳定样品中细胞的生物分子分布的活检装置预计将找到广泛的市场并用于许多器官。这种装置可以促进目前仅限于研究的许多生物分子标记物的临床使用，以通过使用针对每个患者中肿瘤的特定特征的个体化治疗来改善患者的管理。